Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - macrogol 3350, quantity: 13125 mg; potassium chloride, quantity: 46.6 mg; sodium chloride, quantity: 350.7 mg; sodium bicarbonate, quantity: 178.5 mg - powder, oral - excipient ingredients: acesulfame potassium - for effective relief from constipation, treatment of constipation, and treatment of faecal impaction defined as refractory constipation with faecal loading of the rectum and/or colon confirmed by the physical examination of the abdomen and rectum, in adults and children 12 years and over.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sodium bicarbonate, quantity: 178.5 mg; macrogol 3350, quantity: 13125 mg; potassium chloride, quantity: 46.6 mg; sodium chloride, quantity: 350.7 mg - powder, oral - excipient ingredients: acesulfame potassium - for effective relief from constipation, treatment of constipation, and treatment of faecal impaction defined as refractory constipation with faecal loading of the rectum and/or colon confirmed by the physical examination of the abdomen and rectum, in adults and children 12 years and over.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sodium chloride, quantity: 350.7 mg; sodium bicarbonate, quantity: 178.5 mg; potassium chloride, quantity: 46.6 mg; macrogol 3350, quantity: 13125 mg - powder, oral - excipient ingredients: acesulfame potassium; flavour - for effective relief from constipation, treatment of constipation, and treatment of faecal impaction defined as refractory constipation with faecal loading of the rectum and/or colon confirmed by the physical examination of the abdomen and rectum, in adults and children 12 years and over.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - macrogol 3350, quantity: 13125 mg; sodium chloride, quantity: 350.7 mg; potassium chloride, quantity: 46.6 mg; sodium bicarbonate, quantity: 178.5 mg - powder, oral - excipient ingredients: acesulfame potassium - for effective relief from constipation, treatment of constipation, and treatment of faecal impaction defined as refractory constipation with faecal loading of the rectum and/or colon confirmed by the physical examination of the abdomen and rectum, in adults and children 12 years and over.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sodium chloride, quantity: 350.7 mg; sodium bicarbonate, quantity: 178.5 mg; potassium chloride, quantity: 46.6 mg; macrogol 3350, quantity: 13125 mg - powder, oral - excipient ingredients: acesulfame potassium; flavour - for effective relief from constipation, treatment of constipation, and treatment of faecal impaction defined as refractory constipation with faecal loading of the rectum and/or colon confirmed by the physical examination of the abdomen and rectum, in adults and children 12 years and over.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sodium chloride, quantity: 350.7 mg; sodium bicarbonate, quantity: 178.5 mg; potassium chloride, quantity: 46.6 mg; macrogol 3350, quantity: 13125 mg - powder, oral - excipient ingredients: acesulfame potassium; flavour - for effective relief from constipation, treatment of constipation, and treatment of faecal impaction defined as refractory constipation with faecal loading of the rectum and/or colon confirmed by the physical examination of the abdomen and rectum, in adults and children 12 years and over.

Australia - English - Department of Health (Therapeutic Goods Administration)

orpharma pty ltd - sodium phenylbutyrate, quantity: 483 mg/g - granules - excipient ingredients: povidone; ethylcellulose; hypromellose; macrogol 1500; sucrose; hydrolysed maize starch - pheburane (sodium phenylbutyrate) is indicated for the management of hyperammonaemia associated with urea cycle disorders. pheburane? should be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, and protein-free calorie supplements)

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - vildagliptin, quantity: 50 mg; metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: iron oxide yellow; titanium dioxide; hypromellose; macrogol 4000; hyprolose; purified talc; magnesium stearate - for patients with type 2 diabetes mellitus (t2dm):,galvumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients whose diabetes is not adequately controlled on metformin hydrochloride alone or who are already treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. treatment should not be initiated with this fixed-dose combination.,galvumet is indicated in combination with a sulfonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulfonylurea.,galvumet is indicated as add-on to insulin as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 850 mg; vildagliptin, quantity: 50 mg - tablet, film coated - excipient ingredients: macrogol 4000; hypromellose; iron oxide yellow; magnesium stearate; titanium dioxide; hyprolose; purified talc - for patients with type 2 diabetes mellitus (t2dm):,galvumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients whose diabetes is not adequately controlled on metformin hydrochloride alone or who are already treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. treatment should not be initiated with this fixed-dose combination.,galvumet is indicated in combination with a sulfonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulfonylurea.,galvumet is indicated as add-on to insulin as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 500 mg; vildagliptin, quantity: 50 mg - tablet, film coated - excipient ingredients: hypromellose; macrogol 4000; titanium dioxide; magnesium stearate; purified talc; iron oxide yellow; iron oxide red; hyprolose - for patients with type 2 diabetes mellitus (t2dm):,galvumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients whose diabetes is not adequately controlled on metformin hydrochloride alone or who are already treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. treatment should not be initiated with this fixed-dose combination.,galvumet is indicated in combination with a sulfonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulfonylurea.,galvumet is indicated as add-on to insulin as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.